UPDATE: Auriga Downgrades Anthera Pharmaceuticals

According to a research report released earlier today, Auriga has downgraded Anthera Pharmaceuticals Inc.

from Hold to Sell based on excessive valuation. Auriga commented in the report, “We also note interesting competition from upstart CareCloud (private) which boasts a more flexible approach to the revenue cycle and a much friendlier and intuitive user interface. Given the stock's 50% move since its Analyst Day in December, on what we perceive to be weakening fundamentals, we recommend investors take profits as we envision 25% downside from current levels. Our $57 price target is unchanged.” Anthera Pharmaceuticals closed yesterday at $75.65.